GE Medical's insatiable appetite for small firms with technologies it wants has led it to gobble up another one. The company's newest acquisition is Per-Se Technologies, a provider of radiology information systems (RIS). Terms of the agreement were not
GE Medical's insatiable appetite for small firms with technologies it wants has led it to gobble up another one. The company's newest acquisition is Per-Se Technologies, a provider of radiology information systems (RIS). Terms of the agreement were not disclosed.
Per-Se, which has a staff of 22, promises to bolster GE's already strong position in the integrated PACS/RIS market. The company's ProgRIS product will be integrated into GE's PathSpeed PACS with the intent of eventually offering a turnkey PACS/RIS product, according to GE.
For more than a decade, the firm has been methodically adding to its core PACS/RIS capability. GE was among the first multimodality vendors to publicly commit to the development of PACS/RIS 14 years ago. Over the past several years the company has worked closely with Cerner and IDX to offer integrated solutions, combining PathSpeed with both Cerner's RadNet and IDX's IDXRad.
GE began selling Cerner's RadNet product in 1998. The two companies reportedly were on the verge of merging. With GE's purchase last year of ADAC's information systems business, however, Cerner apparently opted to carve its own niche in the integrated systems market. Now GE, like many other PACS and HIS/RIS vendors, has followed suit.
Despite the purchase of ProgRIS and a stated goal of developing a stand-alone PACS/RIS product, GE plans to maintain its relationships with Cerner and IDX and will continue to support integrated solutions developed with these companies, according to Vishal Wanchoo, vice president of radiology systems at GE Medical Systems Information Technologies.
"ProgRIS is a proven technology that is supporting several large healthcare organizations and is an important complement to our image-management offering," Wanchoo said.
As part of the Per-Se purchase, GE gains an installed base of 90 sites, primarily larger hospitals. GE hopes to play off this installed base in the near term to increase its customer base in PACS/RIS, according to Wanchoo.
ProgRIS has been on the market for more than a decade and has long supported bidirectional PACS/RIS communication and remote report access via a Web-enabled browser. The latest iteration of the product, ProgRIS Interactive, was launched at the 1998 RSNA meeting and features enhanced Web-based report retrieval and integrated voice (via embedded IBM MedSpeak Active X technology), images, and text.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.